Department of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.
JAMA. 2023 Jul 25;330(4):349-358. doi: 10.1001/jama.2023.10854.
The large overlap between symptoms of acute sinusitis and viral upper respiratory tract infection suggests that certain subgroups of children being diagnosed with acute sinusitis, and subsequently treated with antibiotics, derive little benefit from antibiotic use.
To assess if antibiotic therapy could be appropriately withheld in prespecified subgroups.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial including 515 children aged 2 to 11 years diagnosed with acute sinusitis based on clinical criteria. The trial was conducted between February 2016 and April 2022 at primary care offices affiliated with 6 US institutions and was designed to evaluate whether symptom burden differed in subgroups defined by nasopharyngeal Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis on bacterial culture and by the presence of colored nasal discharge.
Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) (n = 254) or placebo (n = 256) for 10 days.
The primary outcome was symptom burden based on daily symptom scores on a validated scale (range, 0-40) during the 10 days after diagnosis. Secondary outcomes included treatment failure, adverse events including clinically significant diarrhea, and resource use by families.
Most of the 510 included children were aged 2 to 5 years (64%), male (54%), White (52%), and not Hispanic (89%). The mean symptom scores were significantly lower in children in the amoxicillin and clavulanate group (9.04 [95% CI, 8.71 to 9.37]) compared with those in the placebo group (10.60 [95% CI, 10.27 to 10.93]) (between-group difference, -1.69 [95% CI, -2.07 to -1.31]). The length of time to symptom resolution was significantly lower for children in the antibiotic group (7.0 days) than in the placebo group (9.0 days) (P = .003). Children without nasopharyngeal pathogens detected did not benefit from antibiotic treatment as much as those with pathogens detected; the between-group difference in mean symptom scores was -0.88 (95% CI, -1.63 to -0.12) in those without pathogens detected compared with -1.95 (95% CI, -2.40 to -1.51) in those with pathogens detected. Efficacy did not differ significantly according to whether colored nasal discharge was present (the between-group difference was -1.62 [95% CI, -2.09 to -1.16] for colored nasal discharge vs -1.70 [95% CI, -2.38 to -1.03] for clear nasal discharge; P = .52 for the interaction between treatment group and the presence of colored nasal discharge).
In children with acute sinusitis, antibiotic treatment had minimal benefit for those without nasopharyngeal bacterial pathogens on presentation, and its effects did not depend on the color of nasal discharge. Testing for specific bacteria on presentation may represent a strategy to reduce antibiotic use in this condition.
ClinicalTrials.gov Identifier: NCT02554383.
急性鼻窦炎和病毒性上呼吸道感染的症状有很大的重叠,这表明某些被诊断为急性鼻窦炎并随后接受抗生素治疗的儿童亚组,从抗生素的使用中获益甚微。
评估是否可以适当地在特定亚组中停止抗生素治疗。
设计、地点和参与者:这是一项随机临床试验,纳入了 515 名年龄在 2 至 11 岁之间的儿童,这些儿童根据临床标准被诊断为急性鼻窦炎。该试验于 2016 年 2 月至 2022 年 4 月在 6 家美国机构附属的初级保健办公室进行,旨在评估亚组之间的症状负担是否存在差异,这些亚组的定义依据是鼻咽喉拭子培养中是否存在肺炎链球菌、流感嗜血杆菌或卡他莫拉菌,以及是否存在有色鼻涕。
口服阿莫西林(90mg/kg/d)和克拉维酸(6.4mg/kg/d)(n=254)或安慰剂(n=256),疗程 10 天。
主要结局是基于确诊后 10 天内每天症状评分的症状负担(范围为 0-40)。次要结局包括治疗失败、包括临床显著腹泻在内的不良事件以及家庭资源使用情况。
510 名纳入的儿童中,大多数年龄在 2 至 5 岁(64%)、男性(54%)、白人(52%)且非西班牙裔(89%)。与安慰剂组(10.60 [95%CI,10.27-10.93])相比,阿莫西林和克拉维酸组(9.04 [95%CI,8.71-9.37])的儿童的平均症状评分显著降低(组间差异,-1.69 [95%CI,-2.07-1.31])。抗生素组儿童症状缓解的时间明显短于安慰剂组(分别为 7.0 天和 9.0 天)(P=0.003)。未检测到鼻咽病原体的儿童与检测到病原体的儿童相比,抗生素治疗的效果没有那么明显;未检测到病原体的儿童组的平均症状评分差值为-0.88(95%CI,-1.63-0.12),而检测到病原体的儿童组为-1.95(95%CI,-2.40-1.51)。根据是否存在有色鼻涕,疗效没有显著差异(存在有色鼻涕的组间差异为-1.62 [95%CI,-2.09-1.16],而不存在有色鼻涕的组间差异为-1.70 [95%CI,-2.38-1.03];治疗组和有色鼻涕之间的交互作用 P=0.52)。
在急性鼻窦炎儿童中,对于无鼻咽细菌病原体的儿童,抗生素治疗的效果很小,其效果并不取决于鼻涕的颜色。在就诊时进行特定细菌的检测可能是减少这种情况下抗生素使用的一种策略。
ClinicalTrials.gov 标识符:NCT02554383。